ERBB2 and breast carcinoma: In conclusion, HER2-targeted PET/CT imaging enables the real-time, non-invasive, and quantitative detection of HER2 expression across different lesions in patients with breast cancer, effectively addressing challenges such as re-biopsy difficulties, tumor heterogeneity, and the comprehensive assessment of therapeutic efficacy in clinical settings.